Emily Miller

Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors

Antonia F. Stepan, Kapil Karki, W. Scott McDonald et al. · Journal of Medicinal Chemistry · 2011 · 106 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Pharmacological Characterization of 2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a High-Affinity Antagonist Selective for κ-Opioid Receptors

S. Grimwood, Yang Lü, Anne W. Schmidt et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 59 citations

Medicine, Medicinal Chemistry, Pharmacology +14

The 5-Hydroxytryptamine4 Receptor Agonists Prucalopride and PRX-03140 Increase Acetylcholine and Histamine Levels in the Rat Prefrontal Cortex and the Power of Stimulated Hippocampal θ Oscillations

David E. Johnson, Elena M. Drummond, Sarah Grimwood et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 57 citations

Medicine, Neuroscience, Pharmacology +16

Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.

W Mastropaolo, Zenén Rodríguez Fernández, Emily Miller · Clinical Chemistry · 1986 · 55 citations

Medicine, Gynecology, Oncology +15

Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1 <i>H</i> -pyrazolo-[3,4- <i>b</i> ]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator

Lei Zhang, Gayatri Balan, Gabriela Barreiro et al. · Journal of Medicinal Chemistry · 2014 · 51 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17